In this regard, Yonesaka et al (2008) reported that AREG significantly stimulates the growth of Ctx-sensitive NSCLC cells, the sole inhibition of AREG (either by a neutralising antibody or by siRNA) is sufficient to inhibit NSCLC cell growth, and AREG expression (mRNA or protein) is an appropriate biomarker for identifying patients who will benefit from Ctx treatment in both NSCLC and HNSCC. This evidence concerns the gene AREG and head and neck squamous cell carcinoma.